New drug used to treat breast cancer heralded as 'quite groundbreaking'
By Catholic Online (NEWS CONSORTIUM)
4/6/2014 (3 years ago)
Catholic Online (www.catholic.org)
An important treatment option in the fight against breast cancer may be waiting in the wings. Researchers say a new type of drug could help prevent advanced breast cancer from worsening. The potential is great for breast cancer patients, and makes for a potential blockbuster product for Pfizer.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.
LOS ANGELES, CA (Catholic Online) - Said drug cut in half the risk that cancer would worsen, or progress, researchers said. The median time before the disease progressed or the women died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.
"The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies," Dr. Richard S. Finn, a principal investigator in the study, says. Finn, an oncologist at the University of California, Los Angeles, called the results "quite groundbreaking."
No child need ever go to bed hungry -- Learn how you can help!
Known as palbociclib, the drug also appeared to prolong survival but not by a statistically significant amount. Those who received the drug lived a median of 37.5 months in contrast with 33.3 months for those in the control group.
The results from the Phase 2, or mid-stage, study were presented here at the annual meeting of the American Association for Cancer Research. Palbociclib is considered a jewel in Pfizer's product pipeline, with analysts predicting annual sales of billions of dollars. Amgen is entitled to an eight percent royalty on sales of the drug.
Some investors may have been letdown due to the drug, partly because they were not quite as good as interim results presented about halfway through the trial. At that point, the difference in median progression-free survival was 26.1 months for palbociclib versus 7.5 months for the control group.
Finn stresses that a statistically significant survival benefit should not have been expected at this point because only 61 of the 165 patients in the trial had died. Patients can use other drugs after leaving the trial, which can dilute any effect of palbociclib.
Palbociclib slows the proliferation of cancer cells by inhibiting the activity of two related enzymes involved in cell division; cyclin-dependent kinases 4 and 6.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor. While breast cancer is the initial focus, the drugs are being tested for other cancers.
Breast cancer specialists not involved in the study were encouraged -- but expressed caution. "These results are strikingly positive and with a large potential impact to patients," Dr. José Baselga said in a speech at the conference discussing the results.
Baselga, the physician in chief at the Memorial Sloan-Kettering Cancer Center, also said the results might have been biased because the study investigators, who determined whether tumors had progressed, knew which patients were getting palbociclib.
Dr. Eric P. Winer, chief of women's cancers at the Dana-Farber Cancer Institute in Boston, says larger studies were still needed.
"This is a small Phase 2 trial - not tiny, but not the kind of study that would typically lead to a change in practice," he said.
Copyright 2017 - Distributed by THE CALIFORNIA NETWORK
Pope Francis Prayer Intentions for AUGUST 2017
Artists. That artists of our time, through their ingenuity, may help everyone discover the beauty of creation.
A study performed at Harvard reveals the anatomy of America's massive opioid epidemic, and it is every bit as evil and insidious as one can ... continue reading
Doctors are close to discovering a real life fountain of youth that could theoretically enable patients to live forever. Advances in stem ... continue reading
You have the flu, you just don't know it yet. And inside one cell of your body, the virus is mutating into something terrible. LOS ANGELES, ... continue reading
A 23-year old man living in Britain has opted for his third sex change. LOS ANGELES, CA (California Network) -- A 23-year old man in ... continue reading
Last week, CNN featured Dr. Richard Gallagher in a story about demonic possession. Gallagher is one of a growing number of secular mental ... continue reading
by Catholic Online
- Mother shares tragic photo of dying daughter as she pulled the plug ...
- 'IN OUR HEARTS WE BEAR THE PAIN' Pope Francis opens prayers for all ...
- Why have ONE MILLION South Sudanese people entered Uganda?
- Pope Francis asks for prayers following terror attacks in Spain HD Video
- St. Pius X: Saint of the Day for Monday, August 21, 2017
- Daily Readings for Monday, August 21, 2017
- Pro-Life win? Arkansas makes big moves against abortion-machine ...
- ten commandments
- Pope Francis
- saint agnes
- St Anthony
- 10 commandments
- mary magdalene
- Patron saints
- st bernadette
- pope francis
- St. John
- holy spirit
- morning prayer
- Saint Elizabeth
- St. Augustine
- Saint Anne
- st agnes
- saint monica
- saint catherine
- Saint Lucy
- saint clare
- saint rose
- st rose of lima
- Daily Reading for Tuesday, August 22nd, 2017 HD
- Daily Reading for Monday, August 21st, 2017 HD
- Daily Reading for Sunday, August 20th, 2017 HD
- Charlie Gard's mother opens up about the beautiful life of terminally ill Charlie HD